摘要
目的探讨西妥昔单抗联合DF化疗方案在中晚期食管癌患者中的治疗效果。方法以我院2019年1月至2021年3月收治的80例中晚期食管癌患者为研究对象,用随机数字表法均分为两组,各40例,对照组患者接受DF化疗方案治疗,观察组患者在对照组的基础上联合西妥昔单抗治疗,比较两组患者的近期疗效、肿瘤标志物水平变化及毒副反应发生率。结果观察组患者客观缓解率(72.50%)显著高于对照组(55.00%),组间比较差异有统计学意义(P<0.05);治疗前两组患者的血清癌胚抗原(CEA)与鳞状细胞癌抗原(SCC)水平比较,差异无统计学意义(P>0.05),治疗后观察组患者的CEA与SCC水平显著低于对照组(P<0.05);观察组患者毒副反应发生率(12.50%)显著低于对照组(37.50%),组间比较差异有统计学意义(P<0.05)。结论西妥昔单抗联合DF化疗方案可有效提高近期疗效,降低肿瘤标志物水平,且毒副反应轻微,对中晚期食管癌患者病情控制具有积极意义。
Objective To investigate the efficacy of cetuximab combined with DF chemotherapy in patients with advanced esophageal cancer.Methods 80 patients with advanced esophageal cancer from January 2019 to March 2021 in our hospital were randomly divided into two groups,40 cases in each group.The control group were treated with DF chemotherapy,while the study group with cetuximab on the basis of the control group.The short-term efficacy,changes of tumor markers and the incidence of side effects were compared between 2 groups.Results The recent remission rate(72.50%)of the study group was significantly higher than that of the control group(55.00%,P<0.05).Before treatment,no significant difference were found for CEA and SCC levels between the two groups(P>0.05).After treatment,the levels of CEA and SCC in the study group were significantly lower than those in the control group(P<0.05).The incidence of side effects in the study group(12.50%)was significantly lower than that of the control group(37.50%,P<0.05).Conclusion Cetuximab combined with DF chemotherapy could effectively improve the short-term curative effect,reduce the level of tumor markers,and the toxicity is mild,which has positive significance for the disease control of patients with advanced esophageal cancer.
作者
曹珊珊
苏永立
王春江
吴雪
王勇
CAO Shan-shan;SU Yong-li;WANG Chun-jiang;WU Xue;WANG Yong(Department of Pharmacy,Luoyang Dongfang Hospital,Luoyang,China,471003;Department of Pharmacy,The Third Xiangya Hospital of Central South University,Changsha,China,410000)
出处
《食管疾病》
2021年第2期96-98,共3页
Journal of Esophageal Diseases
